BBRC
Bioscience Biotechnology Research Communications

In-Silico Drug Designing and Molecular Dynamics for Indian Strain of Covid-19 Target Protein from South Africa and Brazil with the Potential Drugs Proved as Good Inhibitor in China

Nishant Kumar Mishra and Pratibha Teotia
Department of Biotechnology (SET), Noida International University, Greater Noida, India.
Corresponding author email: pratibha.teotia@niu.edu.in

ABSTRACT

A joint exploration group of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug separating silicon and a protein movement test, and they revealed 30 specialists with possible antiviral action against SARS-CoV-2 on January 25, 2020. These specialists are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin. A similar report likewise tracked down that Chinese natural meds, for example, RhizomaPolygoniCuspidati and Radix SophoraeTonkinensis may contain dynamic fixings against SARS-COV-2. In this research work, we found by following the techniques of drug designing and molecular dynamics mentioned above that a drug named Carfilzomib (used in top 20 drugs in China against Covid-19) that can be docked against the 7LOP ("South Africa" (B.1.351) and the "Brazil" (P1) variants) of new Indian variant (comes from Brazil and South Africa) and at least cease the activity so that its action of spreading infection can be prevented.

KEY WORDS: REMDESIVIR, SARS-COV-2, RHIZOMA POLYGONI CUSPIDATI, RADIX SOPHORAE TONKINESIS, CINANSERIN AND 7LOP.

INTRODUCTION

The quantity of COVID-19 cases in India expanded at a moderately sluggish speed after the main case was recorded on January 31, 2020. Every day cases topped at around 98,000 cases around September 15, declining consistently for a very long time from that point. A month into 2021, it appeared to be conceivable that India's experience would be not normal for those of the US or Brazil, the two of which saw numerous influxes of the infection and recorded numerous passings inside the previous year.

Coronavirus is brought about by the SARS-CoV-2 infection, an individual from the Covid family. Viruses have been alluded to as a "piece of terrible news enveloped with a protein" by the scholars Jean and Peter Medawar. This expression portrays both the shell of protein particles that ensures the hereditary material of the infection, just as the hereditary material, for this situation a solitary RNA molecule, the "awful news". This molecule contains all the infection requires to duplicate itself once it connects to, and afterward enters, a living cell.

The Background: At the point when an infection taints a living cell, the data contained in its RNA grouping is perused (or "interpreted") to make proteins. A portion of these proteins help the RNA make duplicates of itself ("replication"), others are associated with "wrapping up" the RNA, but other "bundle" this into new infection particles. The last advance in the life-pattern of the infection is for these new infection particles (or virions) to get away from the tainted cell so they can proceed to contaminate others, rehashing this interaction.

Viruses just exist to make duplicates of them. That they cause infection is really accidental to this bigger reason. In any case, these duplicates are now and then defective. On the off chance that the RNA arrangement varies by at least one letters from the first one it was replicated from, this can now and then prompt an alternate protein succession. This change can influence portions of the

Biosc Biotech Res Comm P-ISSN: 0974-6455 E-ISSN: 2321-4007

Identifiers and Pagination
Year: 2021 Vol: 14 No (9) Special Issue
Pages: 101-107

Article Information
Received: 05th May 2021
Accepted after revision: 10th July 2021

DOI: http://dx.doi.org/10.21786/bbrc/14.9.22

infection, modifying the manner in which the infection ties to the cells it taints. It can likewise intrude with the manner in which antibodies tie to explicit uncovered pieces of the infection they were intended to perceive. A few transformations in areas that antibodies look to tie and kill the infection can make procured invulnerability less viable. This is classified "resistant break" and can prompt reviruses. Individuals can likewise get re-contaminated if antibodies melt away with time; however the invulnerable memory of a prior experience with the infection forestalls or restricts sickness.

The Variants: Here are some epidemiological inquiries to which we don't have the foggiest idea about the appropriate responses: Has the B.1.617 variation spread all the more adequately in Maharashtra among February and now, supplanting the more established strain? How much is this variation answerable for the spray in cases outside that state? Is the B.1.36 variation, common in south India, likewise more contagious than the first strain? Assuming this is the case, by what amount? At long last, what is the contamination casualty proportion, related with the new strains? Are there huge changes in the manner fatalities emerging from contamination are circulated across ages? A different line of inquiries has to do with the resistant framework's communication with the new variations.

Does an earlier disease with the first strain or a later immunization shield generously against a contamination from the new variation? Then again, could the result be more terrible? The responses to these inquiries will figure out what we can say about the unfurling of this period of the pandemic. A more contagious illness has a higher related crowd resistance limit, which is the small portion of the populace needed to be inoculated by immunization before those unvaccinated are secured. For the previous strain, 60-70% was a sensible edge. For a quicker spreading new variation, this would be fundamentally bigger. In the event that safe break was huge, the populace powerless to the sickness would need to be extended to incorporate all of India again – we would have returned to where we began in January 2020.

Objective

Our Objectives are:

1. To find the target protein of new Indian variant (comes from Brazil and South Africa).
2. Prepare that target for drug designing criteria.
3. Docking all molecules with target protein active site.
4. To find the best docking score against the target protein with best drug.
5. Energy minimization by simulation with gromacs software of protein-best ligand complex to check the compatibility of best ligand with target protein.

SARS-COV-2 Infection, Replication and Clinical Implications: SARS-CoV-2 can be transmitted human to human by respiratory drops, close contact with unhealthy patients, and conceivably by faecal-oral and airborne contact. It was as of late shown that airborne transmission is profoundly harmful and addresses the predominant course to spread the illness. This finding was acquired dependent on the investigation of the pattern and alleviation measures in three distinct urban communities considered focal points of COVID-19: Wuhan, China, Italy, and New York City, in the time frame from January 23 to May 9, 2020. Significantly, this outcome uncovers that among the embraced alleviation estimates, for example, social separating and wearing of veils, the distinction with and without ordered face covering addresses the determinant in molding the patterns of the pandemic and spread of the sickness.

Dominant part of SARS-CoV-2 tainted people (80 %) are asymptomatic or present gentle manifestations undoubtedly because of a decent insusceptible reaction ready to control the development of the sickness. There is proof that these asymptomatic individuals can taint others with SARS-CoV-2. In the other hand, indicative people may develop to more extreme manifestations and inevitable demise. The most ideal approach to forestall transmission and ailment is to try not to be presented to the infection. Hence, a few suggestions incorporate wash hands regularly, stay away from close contact, cover mouth and nose with a veil, cover hacks and sniffles, and clean and sanitize every now and again contacted surfaces day by day. In such manner, wearing of face covers out in the open relates to the best way to forestall interhuman transmission.

The infection spread principally from individual to-individual between individuals who are in close contact with each other and through respiratory drops delivered when a tainted individual hack, wheezes or talk. The most ideal approach to forestall is to try not to be presented to the infection. Upon cell contact, the infection can enter the cells twoly, either by means of endosomes or plasma film combination. In the two different ways spike proteins (S1 e S2) from SARS-CoV-2 intervene connection to the cell film by restricting to the ACE2 as the section receptor. Then again, virions are taken up into endosomes, spike proteins are enacted by cathepsin L or on the other hand by transmembrane protease serine 2 (TMPRSS2) in closeness to ACE2 receptor, which starts combination of the viral film with the plasma layer. The last system is more averse to trigger an antiviral safe reaction and is more effective for viral replication.

Once inside the cell, viral RNA is delivered, and polyproteins are interpreted. Covid genomic RNA encodes nonstructural proteins (NS), that assume a basic part in viral RNA combination, and primary proteins which are significant for new virion get together. First NS proteins 1a and 1ab are deciphered and severed by the papain-like protease (PIpro) and 3C-like protease (3CLpro) to frame practical NS proteins, for example, helicase or RNA-subordinate RNA polymerase complex (RdRp). Underlying proteins S1, S2, envelope (E), layer (M) are made an interpretation of by ribosomes bound to the endoplasmic reticulum (ER) and introduced on its surface as an arrangement of virion gathering.

The nucleocapsids (N) stay in the cytoplasm and are gathered along with the genomic RNA. The virion antecedent is then shipped from the ER through the Golgi mechanical assembly to the cell surface by means of vesicles. At long last, virions are delivered from the tainted cell through exocytosis and another replication cycle starts. Manifestations and signs related with viral pneumonia like fever, hack, sore throat, cerebral pain, weakness, myalgia and dyspnea are habitually appeared by patients during the beginning of COVID-19.

Moreover, loss of taste or smell and gastrointestinal indications like queasiness, spewing or looseness of the bowels has likewise been accounted for by contaminated patientz. All things considered, illness seriousness is by all accounts emphatically connected with hidden host conditions including age, sex and generally speaking wellbeing. The last appears to assume a basic part in weakness and add to the danger of disease. At the point when extreme and non-serious patients are analyzed, conditions like hypertension, diabetes, cardiovascular and kidney sicknesses increment the danger of disease a few overlap. Momentum helpful treatment for COVID-19 identified with the beginning and physiopathology of the infection.

Albeit observational researchs announced more established age and the presence of comorbidities as hazard factors for expanded infection seriousness in patients with COVID-19, it quickly turned out to be certain that extreme sickness can likewise happen in more youthful patients with no prior ailments. Serious COVID-19 is firmly connected with hyperinflammation as confirmed by more significant levels of C-responsive protein, ferritin and D-dimers in blood just as expanded neutrophil-to-lymphocyte proportion and serum levels of a few fiery cytokines and chemokines.

MATERIAL

(Database):

Ncbi (National Center For Biotechnology Information)
Pubmed
Pdb (Protein Data Bank)
Pubchem
Materials (Softwares):
Open Babel
Autodock
Autodock-Vina
Pymol
Gromacs

METHODOLOGY

Found the target protein ("South Africa" (B.1.351) and the "Brazil" (P1) variants) of new Indian variant (comes from Brazil and South Africa) from literature database PubMed (NCBI) and to download from RCSB-PDB.

Prepared the protein.pdb molecule and all ligand pdb format for docking through AutoDock software.

Downloaded all the potential drugs proved as good inhibitor in China from PubChem and PDB database in 3d-sdf or 3d-pdb format. Changed all sdf format in .pdb by Open Babel software because .pdb format is compatible in AutoDock. Prepared all ligand pdb format for docking through AutoDock software. Docked all ligands with protein one by one and found best drug with best docking score affinity (kcal/mol). Energy minimized by simulation with gromacs software of protein-best ligand complex and checked the compatibility.

RESULT AND DISCUSSION

Target Protein (7LOP)

Preparation of Protein: Opened protein (7LOP) in AutoDock – Deleted all unnecessary chains but chain A – deleted all water molecules – deleted all already present ligands – added all polar hydrogen – added kollman charges on protein chain A – through grid box prepared configuration file and saved the final prepared protein in protein .pdbqt.

Figure 1: Downloaded the target protein 7LOP ("South Africa" (B.1.351) and the "Brazil" (P1) variants) of new Indian variant (comes from Brazil and South Africa) from literature database PubMed (NCBI) and to download from RCSB-PDB.

Figure 2: Prepared the protein.pdb molecule and all ligand pdb format for docking through AutoDock software.



Drug Downloading From Pubchem And Pdb Database Format Change

Preparation of Ligands: In AutoDock one by one opened ligands in pdb format - made their torsion angle non-rotable (0/32) – then saved all in .pdbqt format.

Docking With Autodock-Vina: Docked all ligands with protein one by one and found best drug with best docking score affinity (kcal/mol).

Figure 3: Downloaded all the potential drugs proved as good inhibitor in China from PubChem.



Figure 4: Downloaded all the remaining (which not found in PubChem) potential drugs proved as good inhibitor in China from RCSB-PDB.



Figure 5: Changed all sdf format in .pdb by Open Babel software because .pdb format is compatible in AutoDock.



Figure 6: Prepared all ligand pdb format for docking through AutoDock software.



Figure 7: Carfilzomib (4qw5_GA_3BV) downloaded from RCSB-PDB had the lowest docking score affinity (-9.3 kcal/mol) against our target protein 7LOP (SARS-CoV-2 receptor binding domain) new strain came from South Africa and Brazil



Figure 8: Carfilzomib (4qw5_GA_3BV) shown H-Bond interaction with Glutanin 493 amino acid in PyMOL software



Molecular Dynamics (Energy Minimization/Simulation): Prepared Protein & best ligand complex gro files and topology – Solvation of complex – added ions on topology – energy minimized – NVT equilibrated – NPT equilibrated – production of molecular dynamics - run a 10-ns MD simulation and found lesser H-Bond distance with energy minimized complex structure.

Thus, the results obtained depicts that the drug candidate namely Carfilzomib have the potential to inhibit or slow down the activity of 7LOP ("South Africa" (B.1.351) and the "Brazil" (P1) variants) of new Indian variant (comes from Brazil and South Africa).

Table 1. All other drugs, their databases id, databases name and their docking score against target protein

Drug Name	Database ID	Database Name	Drug Score
Indinavir	Conformer3D_CID_5362440	PubChem	-9
Carfilzomib	4qw5_GA_3BV	RCSB-PDB	-9.3
Ritonavir	3tne_C_RIT	RCSB-PDB	-9.2
Remdesivir	Conformer3D_CID_121304016	PubChem	-9
Darunavir	Conformer3D_CID_213039	PubChem	-8.1
Tipranavir	Conformer3D_CID_54682461	PubChem	-8.8
Fosamprenavir	Conformer3D_CID_131536	PubChem	-8.1
Enzaplatovir	Conformer3D_CID_58406357	PubChem	-7.2
Presatovir	Conformer3D_CID_58029842	PubChem	-8.5
Abacavir	Conformer3D_CID_441300	PubChem	-7.3
Elvitegravir	Conformer3D_CID_5277135	PubChem	-7.5
Maribavir	Conformer3D_CID_471161	PubChem	-7.2
Raltegravir	Conformer3D_CID_54671008	PubChem	-8.5
Montelukast	Conformer3D_CID_5281040	PubChem	-9
Deoxyrhapontin	Conformer3D_CID_5316606	PubChem	-9.2
Polydatin	Conformer3D_CID_5281718	PubChem	-9
Chalcone	Conformer3D_CID_637760	PubChem	-7
Disulfiram	Conformer3D_CID_3117	PubChem	-4.7
Carmofur	Conformer3D_CID_2577	PubChem	-6.1
Shikonin	Conformer3D_CID_479503	PubChem	-8.4
Ebselen	5o40_E_9JT	RCSB-PDB	-6.6
Tideglusib	Conformer3D_CID_11313622	PubChem	-7.7
Px12	Conformer3D_CID_219104	PubChem	-4.5
Tdzd-8	Conformer3D_CID_4124851	PubChem	-5.8
Cinanserin	Conformer3D_CID_5475158	PubChem	-8.4

Figure 10: Energy minimized by simulation with gromacs software of protein-best ligand complex and checked the compatibility



Figure 10: Energy minimization graph by simulation with gromacs software of protein-best ligand complex and checked the compatibility



CONCLUSION

Vaccines are urgently needed to control the coronavirus disease 2019 (COVID-19) pandemic and to help the return to pre-pandemic normalcy. A great many vaccine candidates are being developed, several of which have completed late-stage clinical trials and are reporting positive results. In this research work, we found by following the techniques of drug designing and molecular dynamics mentioned above that a drug named Carfilzomib (used in top 20 drugs in China against Covid-19) that can be docked against the 7LOP ("South Africa" (B.1.351) and the "Brazil" (P1) variants) of new Indian variant (comes from Brazil and South Africa) and at least cease the activity so that its action of spreading infection can be prevented.

REFERENCES

Aguirre-Duarte N. Can people with asymptomatic or pre-symptomatic COVID-19 infect others: a systematic review of primary data. medRxiv. 2020 doi: 10.1101/2020.04.08.20054023.

Center for Disease Control. 2020. Protect Youself.https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html

Chan J.F.W., Yuan S., Kok K.H., To K.K.W., Chu H., Yang J., Xing F., Liu J., Yip C.C.-Y., Poon R.W.-S., Tsoi H.-W., Lo S.K.-F., Chan K.-H., Poon V.K.-M., Chan W.-M., Ip J.-D., Cai J.-P., Cheng V.C.-C., Chen H., Hui C.K.-M., Yuen K.-Y. (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet.;395(10223):514–523.

Channappanavar R., Zhao J., Perlman S. T (2014) cell-mediated immune response to respiratory coronaviruses. Immunol. Res ;59(1–3):118–128. doi: 10.1007/s12026-014-8534-z.

Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L. (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet ;395(10223):507–513.

De Wit E., van Doremalen N., Falzarano D., Munster V.J. (2016) SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol ;14(8):523–534.

Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., Du B., Li L.J., Zeng G., Yuen K.Y., Chen R.C., Tang C.L., Wang T., Chen P.Y., Xiang J., Li S.Y., Wang J.L., Liang Z.J., Peng Y.X., Wei L., Liu Y., Hu Y.H., Peng P., Wang J.M., Liu J.Y., Chen Z., Li G., Zheng Z.J., Qiu S.Q., Luo J., Ye C.J., Zhu S.Y., Zhong N.S. (2020) China medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med.;382(18):1708–1720.

Hindson J. (2020) COVID-19: faecal–oral transmission? Nat. Rev. Gastroenterol. Hepatol.;17:259. doi: 10.1038/s41575-020-0295-7.

Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., Müller M.A., Drosten C., Pöhlmann S. (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell ;181(2):271–280.

Hu Z., Song C., Xu C., Jin G., Chen Y., Xu X., Ma H., Chen W., Lin Y., Zheng Y., Wang J., Hu Z., Yi Y., Shen H. (2020) Clinical characteristics of 24 asymptomatic viruses with COVID-19 screened among close contacts in Nanjing, China. Sci. China Life Sci ;63(5):706–711.

Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.;395(10223):497–506.

Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K.S.M., Lau E.H.Y., Wong J.Y., Xing X., Xiang N., Wu Y., Li C., Chen Q., Li D., Liu T., Zhao J., Liu M., Tu W., Chen C., Jin L., Yang R., Wang Q., Zhou S., Wang R., Liu H., Luo Y., Liu Y., Shao G., Li H., Tao Z., Yang Y., Deng Z., Liu B., Ma Z., Zhang Y., Shi G., Lam T.T.Y., Wu J.T., Gao G.F., Cowling B.J., Yang B., Leung G.M., Feng Z. (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med ;382(13):1199–1207.

Merad M., Martin J.C. (2020) Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. doi: 10.1038/s41577-020-0331-4.

Nelemans T., Kikkert M.(2019) Viral innate immune evasion and the pathogenesis of emerging rna virus viruses. Viruses ;11(10):961. doi: 10.3390/v11100961.

Paderno A., Schreiber A., Grammatica A., Raffetti E., Tomasoni M., Gualtieri T., Taboni S., Zorzi S., Lombardi D., Deganello A., Redaelli De Zinis L.O., Maroldi R., Mattavelli D.(2020) Smell and taste alterations in Covid-19: a cross-sectional analysis of different cohorts. Int. Forum Allergy Rhinol doi: 10.1002/alr.22610.

Sedaghat A.R., Gengler I., Speth M.M. Olfactory dysfunction: a highly prevalent symptom of COVID-19 with public health significance. Otolaryngol. Head. Neck Surg. 2020 doi: 10.1177/0194599820926464. 194599820926464.

Shirato K., Kawase M., Matsuyama S. (2018) Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry. Virology ;517:9–15.

Tian S., Hu N., Lou J., Chen K., Kang X., Xiang Z., Chen H., Wang D., Liu N., Liu D., Chen G., Zhang Y., Li D., Li J., Lian H., Niu S., Zhang L., Zhang J. Characteristics of COVID-19 infection in Beijing. J. Infect. 2020;80(4):401–406.

Van Doremalen N., Bushmaker T., Morris D.H., Holbrook M.G., Gamble A., Williamson B.N., Tamin A., Harcourt

J.L., Thornburg N.J., Gerber S.I., Lloyd-Smith J.O., de Wit E., Munster V.J. (2020) Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. New Engl. J. Med.;382(16):1564–1567. doi: 10.1056/NEJMc2004973.

Xu Y., Li X., Zhu B., Liang H., Fang C., Gong Y., Guo Q., Sun X., Zhao D., Shen J., Zhang H., Liu H., Xia H., Tang J., Zhang K., Gong S. (2020) Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat. Med.;26(4):502–505. doi: 10.1038/s41591-020-0817-4.

Yan C.H., Faraji F., Prajapati D.P., Boone C.E., DeConde A.S. (2020) Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. Int. Forum Allergy Rhinol. doi: 10.1002/alr.22579.

Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., Ji R., Wang H., Wang Y., Zhou Y.(2020) Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int. J. Infect. Dis.;94:91–95. doi: 10.1016/j.ijid.2020.03.017.

Yang X., Yu Y., Xu J., Shu H., Xia J.A., Liu H., Wu Y., Zhang L., Yu Z., Fang M., Yu T., Wang Y., Pan S., Zou X., Yuan S., Shang Y. (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med.;8(5):475–481.

Zhang R., Li Y., Zhang A.L., Wang Y., Molina M.J. (2020) Identifying airborne transmission as the dominant route for the spread of COVID-19. Proc. Natl. Acad. Sci. U. S. A.:202009637. doi: 10.1073/pnas.2009637117.